Opendata, web and dolomites

TRS SIGNED

A paradigm change in the treatment of blinding ocular diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRS project word cloud

Explore the words cloud of the TRS project. It provides you a very rough idea of what is the project "TRS" about.

broad    financing    uveitic    disrupt    medical    shorter    iia    gain    treatment    indication    array    believe    risk    pipeline    market    excellent    treating    inflammation    economic    global    treat    orphan    hundreds    penetration    platform    700    company    people    ocular    candidate    causes    unmet    patients    relieve    correspond    preclinical    reliefs    itself    millions    autoimmune    saving    mechanism    exceed    profits    effect    trial    post    disease    extended    blindness    inflammatory    glaucoma    selecting    reinvested    strategy    shares    capability    re    impose    25    perform    local    tarsius    secure    approved    gt    revenue    expand    500    devastating    therapeutic    corticosteroids    burden    urgent    billion    first    2024    drug    molecule    engineer    worldwide    clinical    infectious    tax    diseases    us    requiring    symptoms    class    merely    steroids    2028    safe    time    immune    commercialization    steroid    inspired    grant    bio    society    exclusivity    launch    lasting   

Project "TRS" data sheet

The following table provides information about the project.

Coordinator
TARSIUS PHARMA LTD 

Organization address
address: 19 YAHALOM ST.
city: ZICHRON YAAKOV
postcode: 3093765
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙461˙500 €
 EC max contribution 2˙423˙050 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TARSIUS PHARMA LTD IL (ZICHRON YAAKOV) coordinator 2˙423˙050.00

Map

 Project objective

Ocular inflammatory diseases – affecting hundreds of millions of people worldwide – impose a significant medical and economic burden on society and can lead to blindness. Today, corticosteroids are the most common method used to treat ocular non-infectious inflammation of any kind. Rather than treating the disease itself, however, steroids merely relieve its symptoms, and long-term use can result in devastating consequences. Our bio-inspired drug candidate is a non-steroid. It approaches inflammatory diseases from within the immune system and was developed to ‘re-engineer’ the immune system. Based on excellent preclinical results, we believe that this approach will have the capability to disrupt the immune mechanism that causes the disease in order to provide patients with a safe and long-lasting therapeutic effect, with the goal of saving them from blindness. Our platform technology has the potential to effectively treat a broad array of autoimmune and inflammatory diseases and to become a first in class, market approved molecule for local treatment of inflammatory ocular diseases. Our first target indication is uveitic glaucoma – a devastating orphan disease requiring urgent treatment and carrying high risk of blindness. Selecting an orphan indication as a market penetration strategy will grant us extended market exclusivity, tax reliefs and shorter time to market. In the project, we will perform a Phase I/IIa clinical trial. We will exploit the trial results to secure financing for further clinical development towards commercialization. The global ocular inflammation treatment market is expected to exceed more than US$ 500 Billion by 2024. As our first target indication has a significant unmet need with no approved treatment, we expect to gain 25% of market shares 5 years post launch, which would correspond to >€700 M in revenue for Tarsius in 2028 for uveitic glaucoma only. Profits will be reinvested to develop our product pipeline and expand our company.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

EVERCAM (2020)

Intelligent Vision System for Improved Communication and Higher Productivity in Construction

Read More  

ALICE (2019)

Armored Liftable anti-Intrusion Control Equipment

Read More